LXRX - Lexicon Pharmaceuticals Inc

-

$undefined

N/A

(N/A)

Lexicon Pharmaceuticals Inc NasdaqGS:LXRX Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Location: 2445 Technology Forest Boulevard, The Woodlands, TX, 77381, United States | Website: https://www.lexpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

162M

Cash

194.8M

Avg Qtr Burn

-41.86M

Short % of Float

20.29%

Insider Ownership

1.15%

Institutional Own.

74.93%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XERMELO® (telotristat ethyl) Details
Carcinoid syndrome diarrhea

Approved

Quarterly sales

INPEFA™ (SOTAGLIFLOZIN) Details
Heart disease, Heart failure

Approved

Quarterly sales

ZYNQUISTA™ (sotagliflozin) Details
Hypertrophic cardiomyopathies

Phase 3

Data readout

Pilavapadin (LX9211) Details
Neuropathy, Diabetic peripheral neuropathy

Phase 2b

Update

LX9851 Details
Obesity, Cardiovascular disease

IND

Submission

ZYNQUISTA™ (sotagliflozin) Details
Type 1 diabetes, Diabetes

Failed

Discontinued